Home » Impax Responds to Warning Letter Regarding Generic Fenofibrate
Impax Responds to Warning Letter Regarding Generic Fenofibrate
The FDA has warned Impax Laboratories for manufacturing violations related to finished pharmaceuticals after agency inspection findings prompted the company’s March recall of fenofibrate capsules.
Generic Line
Generic Line
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May